Other Corporate Information – Page 17

2022-05-31

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022

ATOR-1017 demonstrates an excellent clinical profile as a potential best-in-class 4-1BB monoclonal antibody ATOR-1017 was safe and well tole ...

2022-04-01

Lund, Sweden, April 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for th ...

2022-03-23

Lund, Sweden, March 23, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical P ...

2022-01-19

Lund, Sweden, January 19, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collabor ...

2022-01-18

Lund, Sweden, January 18, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinica ...

2022-01-07

Lund, Sweden, January 7, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Søren Bregenholt, Chief Executive Office ...

2021-12-16

Alligator Bioscience AB (publ)’s ("Alligator" or the “Company") rights issue has now been registered with the Swedish Companies ...

2021-12-16

Lund, Sweden, December 16, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I ...

2021-12-15

Lund, Sweden and Seattle Washington, December 15, 2021 – Alligator Bioscience AB (“Alligator”) and Aptevo Therapeutics (“Aptevo”) (NASDAQ: A ...